570-571 / 1708
SIOP-HR-MB: Biology components
•
Upfront patient selection:
•
Prognostic biomarkers
•
Upfront patient selection:
•
Predictive biomarkers / targeted therapies*
•
Balance risk-factors across randomisation
arms
•
Flexibility
•
Amendments as further risk-factors are validated
•
Targeted therapies as targets/biomarkers are
validated
•
Comprehensive biological studies
•
As per SIOP-PNET5-MB infrastructure/plans
•
Studies across cohorts
•
Funding application submitted
•
Q4 2017 outcome (UK/Sponsor)
•
2018 SIOPE partners